Clinical Trials

492 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT05623020 2026-04-15

MagnetisMM-6

1,116 enrolled

Multiple Myeloma

NCT04181827 2026-04-13

CARTITUDE-4

419 enrolled 10 charts

Multiple Myeloma

NCT04923893 2026-04-13

CARTITUDE-5

743 enrolled

Multiple Myeloma

NCT05083169 2026-04-13

MajesTEC-3

587 enrolled 2 FDA

Multiple Myeloma

NCT05572515 2026-04-13

MajesTEC-9

614 enrolled

Multiple Myeloma, Recurrence

NCT03652064 2026-04-08

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

395 enrolled 11 charts 3 FDA

Multiple Myeloma

NCT04512235 2026-04-07

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)

281 enrolled

Immunoglobulin Light-chain Amyloidosis, Paraproteinemias

NCT01191060 2026-04-06

IFM/DFCI2009

Phase 3 Completed

700 enrolled

Disease Progression, Neoplasms, Plasma Cell

NCT04566328 2026-04-03

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

1,450 enrolled

Multiple Myeloma

NCT04975997 2026-04-03

EXCALIBER-RRMM

939 enrolled

Multiple Myeloma

NCT06918002 2026-04-02

ElLen

824 enrolled

Multiple Myeloma

NCT06413498 2026-03-27

iMMagine-3

450 enrolled

Multiple Myeloma

NCT05519085 2026-03-24

SUCCESSOR-1

810 enrolled

Multiple Myeloma, Recurrence

NCT04504825 2026-03-17

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)

125 enrolled

Immunoglobulin Light-chain Amyloidosis, Paraproteinemias

NCT05257083 2026-03-17

CARTITUDE-6

759 enrolled

Multiple Myeloma

NCT06158841 2026-03-13

CERVINO

380 enrolled

Multiple Myeloma

NCT06208150 2026-03-13

MonumenTAL-6

795 enrolled

Multiple Myeloma

NCT07391657 2026-03-12

DURGA-4

508 enrolled

Multiple Myeloma

NCT03729804 2026-03-04

(COBRA)

250 enrolled

Multiple Myeloma

NCT05804032 2026-02-18

Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma

Phase 3 Completed

514 enrolled

LymphoidPlasma cell

Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Paraproteinemias

NCT03710603 2026-02-10

Perseus

709 enrolled 17 charts 2 FDA

Multiple Myeloma

NCT04751877 2026-02-10

Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years).

270 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00572169 2026-02-05

UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy

177 enrolled

Multiple Myeloma

NCT03617731 2026-02-03

Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)

662 enrolled

Multiple Myeloma

NCT07297329 2026-01-29

A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

292 enrolled

Multiple Myeloma

NCT01208662 2026-01-22

DFCI 10-106

729 enrolled 29 charts